PROKIDNEY Business Summary

ProKidney Corp. (PROK) is a clinical-stage biotechnology company that operates a pre-commercial business model centered on the development and eventual commercialization of autologous cell therapies. Revenue is currently generated through strategic licensing agreements, R&D collaborations, and milestone payments, with long-term growth predicated on future product sales of its lead candidate, rilparencel (formerly REACT®). The company’s primary business segment is regenerative medicine, specifically focused on its proprietary cell therapy platform designed to treat late-stage chronic kidney disease (CKD) by utilizing a patient’s own renal cells to stabilize or improve kidney function. ProKidney competes directly with firms such as Calliditas Therapeutics, Travere Therapeutics, and Enyo Pharma. Within this competitive landscape, ProKidney distinguishes itself as a pioneer in disease-modifying cellular treatments for diabetic CKD, aiming to fill a critical gap in the market by delaying the progression to dialysis. The company was founded in 2015 by Pablo Legorreta, the founder of Royalty Pharma, and Dr. Tim Bertram, a veteran in regenerative medicine. The current leadership team is headed by CEO Dr. Bruce Culleton, who previously served as Vice President and General Manager at CVS Kidney Care, and CFO James Coulston, who brings a background from Banner Life Sciences. Other key executives include Dr. Ulrich Ernst, EVP of Technical Operations, and Todd C. Girolamo, Chief Legal Officer. ProKidney’s board and investor base are notable for their deep industry pedigree, featuring Chairman Pablo Legorreta, Dr. Brian J.G. Pereira (CEO of Visterra), and Dr. Uma Sinha (CSO of BridgeBio). Significant institutional backing is provided by Chamath Palihapitiya’s Social Capital and the Slim family’s Control Empresarial de Capitales, underscoring the company’s strong financial and strategic positioning.